Correction to Author’s Academic Degrees

Abstract

In addition, he had a patent to a tyrosine kinase inhibitor (TKI) in neurodegeneration pending and issued and is an inventor on several US and international Georgetown University patents to use nilotinib and other TKIs as a treatment for neurodegenerative diseases. Dr Moussa, his laboratory, and Georgetown University previously received some income from the licensing of the technology to Axovant Science, which was spun out to a start-up company (KiefeRX LLC) from which Dr Moussa receives consulting fees.